C. Ola Landgren: The 11th Annual Miami Myeloma MRD Meeting was a huge success!
C. Ola Landgren, Professor of Medicine, Chief of the Division of Myeloma at University of Miami and Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“WOW!!!
The 11th Annual “Miami Myeloma MRD Meeting 2025” was a HUGE success! We had almost 100 attendees in-person and 807 attendees online from across the U.S. and internationally!
The meeting covered all the latest news on MRD testing in relation to biology, treatment, and clinical outcomes. Importantly, we also covered patient perspectives on MRD testing. And we discussed the implications of FDA’s ODAC 2024 approval of MRD as an early endpoint for accelerated drug approval in multiple myeloma.
It was fantastic to see representation by all the leaders and all the leading institutions in the field. Impressive presentations, outstanding discussions, sharing of new ideas, and lots of networking!
The meeting was hosted by Sylvester Comprehensive Cancer Center’s Myeloma Institute at University of Miami in collaboration with Multiple Myeloma Research Foundation – MMRF, International Myeloma Foundation, and HealthTree Foundation for Multiple Myeloma. Media partners for the meeting were World Health Communications and Video Journal of Hematology and Hematological Oncology (VJHemOnc).
All the presentations and sessions from “Miami Myeloma MRD Meeting 2025” were recorded and will be available online shortly.
We hope to see you all again next year at “Miami Myeloma MRD Meeting 2026″ in beautiful Miami! Stay tuned for more details!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023